-
Talimogene laherparepvec, sold
under the
brand name
Imlygic, is a
biopharmaceutical medication used to
treat melanoma that
cannot be
operated on; it is...
-
acquired by Sanofi.
Leukine is now
owned by
Partner Therapeutics (PTx).
Imlygic was
approved by the US FDA in
October 2015, and in
December 2015 by the...
- Dublin, Ireland, in March. In May,
Amgen acquired BioVex,
developer of
Imlygic (talimogene laherparepvec). In December,
Amgen and
Watson Pharmaceuticals...
-
National Cancer Institute. 25
November 2015.
Retrieved 23 July 2021. "
Imlygic".
European Medicines Agency (EMA). 17
September 2018. "First gene therapy...
- for
adenosine deaminase deficiency (ADA-SCID)
Talimogene laherparepvec (
Imlygic):
treatment for
melanoma in
patients who have
recurring skin
lesions Tisagenlecleucel...
-
strain for
bladder invasive cancer.
Talimogene laherparepvec (T-VEC or
Imlygic) is a
vaccine for
advanced oncolytic melanoma "Preventive
vaccine vs therapeutic...
-
selectively infect tumor cells because of
their defective anti-viral response.
Imlygic, an
attenuated herpes simplex virus, has been
genetically engineered to...
- 107 (10): 1373–1379. doi:10.1111/cas.13027. PMC 5084676. PMID 27486853. "
Imlygic label" (PDF). FDA.
October 2015.
Retrieved 16
October 2016. For
label updates...
-
activity in
murine models, with
several clinical trials under investigation.
IMLYGIC (talimogene laherparepvec) was the
first FDA-approved
oncolytic virus for...
